November 1, 1996Diabetes Care
Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
Why the study?
Does glimepiride improve fasting plasma glucose and HbA1c in previously treated patients with NIDDM?
Population
416 previously treated patients with NIDDM (non-insulin-dependent diabetes mellitus)
Comparison
Glimepiride 8 mg once daily, 4 mg twice daily… vs Placebo for 14 weeks
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
14 weeks
Authors
Discussion
Loading...
Member takes
Implication
Glimepiride offers effective glycemic control in NIDDM; confirms sulfonylurea benefits in this RCT population.
Structured PICO
Does glimepiride improve fasting plasma glucose and HbA1c in previously treated patients with NIDDM?
P
Population
416 previously treated patients with NIDDM (non-insulin-dependent diabetes mellitus)
I
Intervention
Glimepiride 8 mg once daily, 4 mg twice daily, 16 mg once daily, or 8 mg twice daily for 14 weeks
C
Comparator
Placebo for 14 weeks
O
Outcome
Fasting plasma glucose (FPG) and HbA1c at 14 weekssurrogate
Glimepiride effectively lowers fasting plasma glucose and HbA1c in patients with NIDDM, with 8 mg once daily providing maximum effectiveness.
Cite This Study
Rosenstock et al. (1996) studied this question.